adalimumab-adbm (Cyltezo) vs adalimumab-afzb (Abrilada)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02871635 · Phase 3 · completed

This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.

Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.

Reported efficacy

Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)

Result source: NCT02871635

adalimumab-afzb (Abrilada)

Marketed by Pfizer

Approved in Crohn's Diseasemonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)adalimumab-afzb (Abrilada)
Clinical remission (induction)—Not reported—Not reported
Endoscopic response (induction)—Not reported—Not reported
Clinical remission (maintenance)68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635—Not reported
Endoscopic response (maintenance)—Not reported—Not reported

Clinical remission (induction)

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

Endoscopic response (induction)

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

Clinical remission (maintenance)

adalimumab-adbm (Cyltezo)
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635
adalimumab-afzb (Abrilada)
—Not reported

Endoscopic response (maintenance)

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-afzb (Abrilada): no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 4 of 4 rows · adalimumab-afzb (Abrilada): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-adbm (Cyltezo)
Dropout rate
25%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Discontinued due to AEs
5.6%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Serious AEs
—BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
8.3%BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
2.8%BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Most frequent reported AEs
arthralgia 8.3%
respiratory tract infection 6.9%
crohn's disease 5.6%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
nasopharyngitis 6.9%
weight increased 4.2%
arthralgia 2.8%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-adbm (Cyltezo)

CDAI ≥ 70 88% (n=68) vs 93.1% (n=72) Humira EU @ 4wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
87.4% (n=68) vs 87.4% (n=72) Humira EU @ 24wk
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
Clinical Remission 68.6% (n=68) vs 76.2% (n=72) Humira EU @ 24wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Psoriasismonoclonal antibody
Weak signal

NCT03210259 · Phase 3 · completed

After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

adalimumab-afzb (Abrilada)

Marketed by Pfizer

Approved in Psoriasismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)adalimumab-afzb (Abrilada)
PASI 75—Not reported—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported—Not reported
DLQI, change—Not reported—Not reported

PASI 75

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

PASI 90

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

PASI 100

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

sPGA 0/1

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

DLQI, change

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

adalimumab-afzb (Abrilada): no structured comparison results are available for Psoriasis.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02137226 · Phase 3 · completed

The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.

No aligned efficacy figure on record for this race.

adalimumab-afzb (Abrilada)

Marketed by Pfizer

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02480153 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled Phase 3 trial in 597 patients comparing PF-06410293 with adalimumab-EU on a hard clinical endpoint: ACR20 response at Week 12. The primary equivalence analysis succeeded, with the 95% confidence interval for the response rate difference falling entirely within the prespecified -14% to +14% margin (observed difference -2.98%, 95% CI -10.38% to 4.44%). The large sample size, blinding, active comparator, and met primary endpoint together provide strong evidence of equivalent efficacy.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33% (met)

Result source: NCT02480153

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)adalimumab-afzb (Abrilada)
ACR20—Not reported68.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153
ACR50—Not reported62.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153
ACR70—Not reported36.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
68.3% vs 71.3%vs Adalimumab-EUwk 12 · n 297NCT02480153
11 other results
  • 82.7% vs 79.3% wk 52 · n 283 · Phase 3 · secondary NCT02480153
  • 82.3% vs 78.5% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 83.4% vs 77.8% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 86.6% vs 82.2% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 83.5% vs 78% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 86.6% vs 84.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 78.1% vs 73.7% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 69.4% vs 68% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 61.3% vs 59.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 51.9% vs 52.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 31.3% vs 32% wk 2 · n 297 · Phase 3 · secondary NCT02480153

ACR50

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
62.9% vs 55.6%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 64.3% vs 49.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 61.1% vs 51.9% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 59.7% vs 49.6% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 59.6% vs 54.7% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 61.8% vs 56.3% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 45.1% vs 47% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 39.7% vs 39.7% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 34% vs 33.3% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 27.6% vs 27.3% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 17.8% vs 14.3% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 8.4% vs 6% wk 2 · n 297 · Phase 3 · secondary NCT02480153

ACR70

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
36.4% vs 31.9%vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • 38.5% vs 32.6% wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • 36% vs 26.7% wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • 33.9% vs 30.4% wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • 29.6% vs 31% wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • 31.1% vs 30.4% wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • 21.5% vs 22% wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • 16.5% vs 19% wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • 12.5% vs 11.7% wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • 8.1% vs 8.7% wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • 3.7% vs 3.7% wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • 0.7% vs 2% wk 2 · n 297 · Phase 3 · secondary NCT02480153

DAS28-CRP remission

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported

HAQ-DI, change

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
-0.7 vs -0.7vs Adalimumab-EUwk 52 · n 283NCT02480153
11 other results
  • -0.7 vs -0.7 wk 44 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 36 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 30 · n 283 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 297 · Phase 3 · secondary NCT02480153
  • -0.7 vs -0.7 wk 26 · n 283 · Phase 3 · secondary NCT02480153
  • -0.6 vs -0.6 wk 18 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 12 · n 297 · Phase 3 · secondary NCT02480153
  • -0.5 vs -0.5 wk 8 · n 297 · Phase 3 · secondary NCT02480153
  • -0.4 vs -0.5 wk 6 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.4 wk 4 · n 297 · Phase 3 · secondary NCT02480153
  • -0.3 vs -0.3 wk 2 · n 297 · Phase 3 · secondary NCT02480153

Modified Sharp score, change

adalimumab-adbm (Cyltezo)
—Not reported
adalimumab-afzb (Abrilada)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · adalimumab-afzb (Abrilada): 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-afzb (Abrilada)
Dropout rate
—Period 1: PF-06410293a
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
Discontinued due to AEs
—Period 1: PF-06410293a
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
—Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—
NCT04230213 · Phase 3
Serious AEs
4%Period 1: PF-06410293a
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
1.4%Period 2: PF-06410293/PF-06410293
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
3.5%Period 3: PF-06410293/PF-06410293/
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
1.4%
NCT04230213 · Phase 3
Most frequent reported AEs
a
viral upper respiratory tract infection 7.1%
rheumatoid arthritis 1.7%
nasopharyngitis 0%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 3 more results
viral upper respiratory tract infection 5.3%
rheumatoid arthritis 1.4%
nasopharyngitis 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
nasopharyngitis 5%
rheumatoid arthritis 4.7%
viral upper respiratory tract infection 0.4%
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
sars-cov-2 test positive 8.5%
covid-19 7.5%
erythema 2.8%
NCT04230213 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-afzb (Abrilada)

ACR20 68.35% (n=297) vs 71.33% (n=300) Adalimumab-EU @ 12wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
31.3% (n=297) vs 32% (n=300) Adalimumab-EU @ 2wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 93 Participants as posted
51.9% (n=297) vs 52.3% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 154 Participants as posted
61.3% (n=297) vs 59.7% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 182 Participants as posted
69.4% (n=297) vs 68% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 206 Participants as posted
78.1% (n=297) vs 73.7% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 232 Participants as posted
83.5% (n=297) vs 78% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 248 Participants as posted
86.6% (n=283) vs 84.4% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 245 Participants as posted
86.6% (n=283) vs 82.2% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 245 Participants as posted
83.4% (n=283) vs 77.8% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 236 Participants as posted
82.3% (n=283) vs 78.5% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 233 Participants as posted
82.7% (n=283) vs 79.3% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 234 Participants as posted
ACR20 88.4% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 229 Participants as posted
show 4 more results
88.8% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 230 Participants as posted
87.3% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 226 Participants as posted
84.6% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 219 Participants as posted
83.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 216 Participants as posted
ACR50 8.4% (n=297) vs 6% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 25 Participants as posted
show 11 more results
17.8% (n=297) vs 14.3% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 53 Participants as posted
27.6% (n=297) vs 27.3% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 82 Participants as posted
34% (n=297) vs 33.3% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
39.7% (n=297) vs 39.7% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
45.1% (n=297) vs 47% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 134 Participants as posted
59.6% (n=297) vs 54.7% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
61.8% (n=283) vs 56.3% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
59.7% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 169 Participants as posted
61.1% (n=283) vs 51.9% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 173 Participants as posted
64.3% (n=283) vs 49.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 182 Participants as posted
62.9% (n=283) vs 55.6% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 178 Participants as posted
ACR50 68.3% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
show 4 more results
67.6% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 175 Participants as posted
68.3% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 177 Participants as posted
69.1% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 179 Participants as posted
71.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 185 Participants as posted
ACR70 0.7% (n=297) vs 2% (n=300) Adalimumab-EU @ 2wk
responder rate · % of participants
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 2 Participants as posted
show 11 more results
3.7% (n=297) vs 3.7% (n=300) Adalimumab-EU @ 4wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 11 Participants as posted
8.1% (n=297) vs 8.7% (n=300) Adalimumab-EU @ 6wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 24 Participants as posted
12.5% (n=297) vs 11.7% (n=300) Adalimumab-EU @ 8wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 37 Participants as posted
16.5% (n=297) vs 19% (n=300) Adalimumab-EU @ 12wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 49 Participants as posted
21.5% (n=297) vs 22% (n=300) Adalimumab-EU @ 18wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 64 Participants as posted
29.6% (n=297) vs 31% (n=300) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
31.1% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 26wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 Participants as posted
33.9% (n=283) vs 30.4% (n=135) Adalimumab-EU @ 30wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 96 Participants as posted
36% (n=283) vs 26.7% (n=135) Adalimumab-EU @ 36wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 102 Participants as posted
38.5% (n=283) vs 32.6% (n=135) Adalimumab-EU @ 44wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 109 Participants as posted
36.4% (n=283) vs 31.9% (n=135) Adalimumab-EU @ 52wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
ACR70 39.8% (n=259) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 Participants as posted
show 4 more results
39% (n=259) @ 56wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 101 Participants as posted
43.2% (n=259) @ 66wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 112 Participants as posted
45.6% (n=259) @ 76wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 118 Participants as posted
49.4% (n=259) @ 78wk*
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 128 Participants as posted
Tender Joint Count -7.5 vs -7.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-10.2 vs -10.7 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -13.1 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-14.2 vs -15.2 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-15.4 vs -16.1 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-16.8 vs -17.3 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -19.2 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.4 vs -20.1 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19 vs -19.5 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.7 vs -20.1 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.4 vs -21.5 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-18.9 vs -21 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Tender Joint Count -19.3 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-19.4 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-19.5 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.6 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-20.5 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -5.7 vs -6.1 Adalimumab-EU joints @ 2wk
absolute change · joints
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-7.7 vs -8.2 Adalimumab-EU joints @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9 vs -9.7 Adalimumab-EU joints @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-9.8 vs -11 Adalimumab-EU joints @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-10.4 vs -11.8 Adalimumab-EU joints @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-11.3 vs -13 Adalimumab-EU joints @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.2 vs -13.6 Adalimumab-EU joints @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.3 vs -13.3 Adalimumab-EU joints @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.4 vs -14.2 Adalimumab-EU joints @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.8 vs -14.7 Adalimumab-EU joints @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-12.6 vs -14.2 Adalimumab-EU joints @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Swollen Joint Count -12.8 joints @ 52wk
absolute change · joints
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-12.9 joints @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13 joints @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.3 joints @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-13.4 joints @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -20.7 vs -20.5 Adalimumab-EU score @ 2wk
absolute change · score
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 11 more results
-28.9 vs -29 Adalimumab-EU score @ 4wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-32.6 vs -33 Adalimumab-EU score @ 6wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-35.6 vs -37.1 Adalimumab-EU score @ 8wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-40.4 vs -40.5 Adalimumab-EU score @ 12wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-44.2 vs -44.2 Adalimumab-EU score @ 18wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.2 vs -46.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.7 vs -45.5 Adalimumab-EU score @ 26wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -46.5 Adalimumab-EU score @ 30wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.3 vs -45.4 Adalimumab-EU score @ 36wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.1 vs -46.9 Adalimumab-EU score @ 44wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-47.9 vs -48.4 Adalimumab-EU score @ 52wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Physician Global Assessment -48.9 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-50.5 score @ 56wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-49.4 score @ 66wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-50.9 score @ 76wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-52.3 score @ 78wk
NCT02480153 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3

+ 46 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · adalimumab-afzb (Abrilada)'s landscape